Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $43.3800 (13.5%) ($39.1300 - $43.6700) on Mon. Nov. 14, 2011. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.76% (three month average) | RSI | 72 | Latest Price | $43.3800(13.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 2.2% a day on average for past five trading days. | Weekly Trend | VBIV advances 2.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(18%) REMX(10%) XAR(9%) EEM(8%) EWI(8%) | Factors Impacting VBIV price | VBIV will decline at least -3.38% in a week (0% probabilities). TLT(-2%) USO(1%) TIP(2%) XLU(3%) SHY(3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.38% (StdDev 6.76%) | Hourly BBV | 0 () | Intraday Trend | 10.9% | | | |
|
5 Day Moving Average | $39.8(8.99%) | 10 Day Moving Average | $39.55(9.68%) | 20 Day Moving Average | $38.94(11.4%) | To recent high | -6.9% | To recent low | 102.1% | Market Cap | $10.006b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |